January 2025 in “Cell Communication and Signaling” CXXC5 can both suppress and promote cancer, making it a complex target for treatment.
1 citations
,
September 2025 in “The Oncologist” Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.
3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
15 citations
,
October 2014 in “Journal of Investigative Dermatology” New treatments targeting the Hedgehog pathway can help treat advanced skin cancer but may have side effects and their effectiveness in early stages is unknown.
September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
Baricitinib shows promise for treating alopecia areata with mild side effects.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia”
4 citations
,
September 2020 in “Cell division” XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
April 2026 in “Future Medicinal Chemistry” PROTACs have become a breakthrough in medicine by effectively targeting and degrading specific proteins to treat diseases.
15 citations
,
January 2014 in “Medicinal chemistry” Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.
March 2024 in “International Journal of Dermatology” Baricitinib improved nail condition and hair regrowth in a patient with alopecia and nail abnormalities.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
127 citations
,
August 2016 in “The oncologist” Understanding and managing side effects of hedgehog pathway inhibitors can improve treatment for advanced basal cell carcinoma.
25 citations
,
January 2011 in “Annals of Dermatology” Erlotinib can cause hair loss as a side effect.
January 2024 in “Wiadomości Lekarskie” The ABI1 gene contributes to prostate cancer progression and treatment resistance.
35 citations
,
January 2004 in “European journal of oncology nursing” Capecitabine is as effective as intravenous treatments with fewer side effects, but requires careful management of Hand-foot syndrome and patient education.
8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
January 2021 in “Research Portal Denmark” Tofacitinib helped a man with alopecia totalis regrow all his hair.
December 2025 in “Orvosi Hetilap” Baricitinib is effective and safe for treating alopecia areata.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
9 citations
,
April 2010 in “Lung cancer” Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.
August 2024 in “Dermatology and Therapy” Vorasidenib can cause unusual hair growth.
May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
January 2026 in “International Journal of Molecular Sciences” Hedgehog pathway inhibitors could be effective in treating melanoma.
September 2023 in “International journal of molecular sciences” Targeting lipid metabolism can help treat advanced, resistant cancers.